Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Massimo Di Nicola et al.|Journal of Clinical Oncology|2010Cited by 167
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Liliana Devizzi, Andrea Riccardo Filippi et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 48
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Corrado Tarella, Alessandra Dondi et al.|Haematologica|2019Cited by 19
Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL TrialCorrado Tarella, Marco Ladetto, Alessandra Dondi et al.|Blood|2013Cited by 4
A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.Corrado Tarella, Paolo Corradini, Umberto Vitolo et al.|Blood|2009Cited by 4